Matthew D Durbin, Lindsey R Helvaty, Alyx Posorske, Samuel Zhang, Manyan Huang, Ming Li, Daniel Abreu, Korre Fairman, Gabrielle C Geddes, Benjamin M Helm, Benjamin J Landis, Alexis McEntire, Dana K Mitchell, Stephanie M Ware
Congenital heart disease (CHD) is the most common birth defect and a leading cause of infant mortality. CHD often has a genetic etiology and recent studies demonstrate utility in genetic testing. In clinical practice, decisions around genetic testing choices continue to evolve, and the incorporation of rapid genome sequencing (rGS) in CHD has not been well studied. Though smaller studies demonstrate the value of rGS, they also highlight the burden of results interpretation. We analyze genetic testing in CHD at two time-points, in 2018 and 2022-2023, across a change in clinical testing guidelines from chromosome microarray (CMA) to rGS...
March 20, 2024: Research Square